Human Psychopharmacology: Clinical and Experimental
June 23, 2020
Edward James, Thomas L Robertshaw, Mathew Hoskins et al.
29 citations
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long‐term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight strengths and weaknesses in...
FOCUS: The Journal of Lifelong Learning in Psychiatry
June 17, 2020
Franklin King, Rebecca Hammond
13 citations
Although psychedelics initially showed promise in treating anxiety disorders, psychedelics were criminalized and research halted in the early 1970s. A subsequent resurgence of research into psychiatric benefits of psychedelic-assisted psychotherapy in the last 20 years has led to a potential paradigm shift in the treatment of numerous psychiatric disorders, including anxiety disorders. Despite...
Open Repository of the University of Porto (University of Porto)
June 5, 2020
Rui Pedro Leal Andrade
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety....
Medicine, Health Care, and Philosophy
May 28, 2020
Adam Greif, Martin Šurkala
25 citations
In the present paper, we discuss the ethics of compassionate psychedelic psychotherapy and argue that it can be morally permissible. When talking about psychedelics, we mean specifically two substances: psilocybin and MDMA. When administered under supportive conditions and in conjunction with psychotherapy, therapies assisted by these substances show promising results. However, given the...
The Journal of Antibiotics
May 12, 2020
David E. Nichols
184 citations
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. South American Aztec Indians referred to them as teonanacatl, meaning "god's flesh," and they were used in religious and healing rituals. Spanish missionaries in the 1500s attempted to destroy all records and evidence of the use of these mushrooms. Nevertheless,...
Journal of Psychoactive Drugs
May 7, 2020
Shevaugn Johnson, Q. C. Black
ABSTRACT Preliminary evidence supports the efficacy of psychedelics in the alleviation of cluster headache and mental health problems. We describe a case of an individual with cluster headache and mood disorder who claims to have benefited from her use of psychedelics. A forty-eight-year-old woman was referred to a private Australian mental health clinic for the management of chronic pain and...
The Brown University Psychopharmacology Update
May 6, 2020
1 citation
Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of research justifies continued investigation, a literature review concludes. The review found the most significant evidence supporting use of psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA). Both of these drugs have been given “breakthrough...
Neuropsychopharmacology
May 5, 2020
Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al.
66 citations
For most psychiatric disorders, including alcohol use disorder (AUD), approved pharmacological treatments are limited in their effectiveness, and new drugs that can easily be translated into the clinic are needed. Currently, great hope lies in the potential of psychedelics to effectively treat AUD. The primary hypothesis is that a single session of psychedelic-guided psychotherapy can restore...
Psychopharmacology
May 1, 2020
Toby Lea, Nicole Amada, Henrik Jungaberle et al.
The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...
UNC Libraries
April 22, 2020
David E. Nichols
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. Their origin predates written history, and they were employed by early cultures in many sociocultural and ritual contexts. After the virtually...